Last reviewed · How we verify

IgY — Competitive Intelligence Brief

IgY (IgY) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal immunoglobulin Y (IgY) therapeutic. Area: Respiratory / Infectious Disease.

phase 3 Polyclonal immunoglobulin Y (IgY) therapeutic Pseudomonas aeruginosa lipopolysaccharide and surface antigens Respiratory / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

IgY (IgY) — Mukoviszidose Institut gGmbH. IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IgY TARGET IgY Mukoviszidose Institut gGmbH phase 3 Polyclonal immunoglobulin Y (IgY) therapeutic Pseudomonas aeruginosa lipopolysaccharide and surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal immunoglobulin Y (IgY) therapeutic class)

  1. Mukoviszidose Institut gGmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IgY — Competitive Intelligence Brief. https://druglandscape.com/ci/igy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: